Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase was written by Currie, Kevin S.;Kropf, Jeffrey E.;Lee, Tony;Blomgren, Peter;Xu, Jianjun;Zhao, Zhongdong;Gallion, Steve;Whitney, J. Andrew;Maclin, Deborah;Lansdon, Eric B.;Maciejewski, Patricia;Rossi, Ann Marie;Rong, Hong;Macaluso, Jennifer;Barbosa, James;Di Paolo, Julie A.;Mitchell, Scott A.. And the article was included in Journal of Medicinal Chemistry in 2014.Safety of 4-Methylpiperidin-4-ol hydrochloride This article mentions the following:
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncol. disease indications. The most advanced Syk inhibitor, R406, (or its prodrug form fostamatinib), has shown efficacy in multiple therapeutic indications, but its clin. progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of R406. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein the authors report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clin. evaluation for autoimmune and oncol. indications. In the experiment, the researchers used many compounds, for example, 4-Methylpiperidin-4-ol hydrochloride (cas: 586375-35-1Safety of 4-Methylpiperidin-4-ol hydrochloride).
4-Methylpiperidin-4-ol hydrochloride (cas: 586375-35-1) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Safety of 4-Methylpiperidin-4-ol hydrochloride
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem